B. Riley upgraded shares of Zynex (NYSE:ZYXI) from a neutral rating to a buy rating in a report issued on Wednesday morning, FinViz reports. The brokerage currently has $28.00 target price on the stock.
Separately, HC Wainwright cut Zynex from a buy rating to a neutral rating in a research report on Tuesday, May 19th.
Shares of NYSE ZYXI opened at $19.12 on Wednesday. Zynex has a one year low of $7.51 and a one year high of $29.73. The business’s fifty day moving average price is $23.42 and its 200-day moving average price is $16.04.
Zynex, Inc, through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and TENSWave, a dual channel TENS device.
Recommended Story: Arbitrage
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.